Pheast Therapeutics Presents Preclinical Data on PHST677, a

The New Frontier of Cancer Immunotherapy: Beyond T-Cells

For years, the gold standard of immunotherapy has been the T-cell. From CAR-T therapies to checkpoint inhibitors like PD-1 blockers, the focus has been on the adaptive immune system. But a significant shift is happening. We are now entering the era of innate immune activation, specifically targeting macrophages.

Macrophages are the “first responders” of the immune system. In a healthy state, they detect and consume cancer cells through a process called phagocytosis. However, tumors are masters of disguise, employing “don’t eat me” signals to remain invisible to these cellular scavengers.

The emerging trend is no longer just about “releasing the brakes” on T-cells, but about actively training macrophages to “feast” on tumors. This pivot toward the innate immune system offers a potential lifeline for patients with “cold” tumors—cancers that don’t naturally attract T-cells and are therefore resistant to traditional immunotherapies.

Unmasking the “Don’t Eat Me” Signals

The discovery of the CD47-SIRPα axis first alerted the medical community to “don’t eat me” signals. Since then, the race has been on to find other checkpoints that tumors use to evade the innate immune system. Recent breakthroughs have highlighted CD24 and, more recently, CDH1 (E-cadherin) as critical targets.

CDH1 was long known for its role in cell-to-cell adhesion—essentially the “glue” that holds epithelial tissues together. However, new data reveals it also acts as a negative regulator of macrophage phagocytosis. When CDH1 is upregulated, it tells macrophages to stay away, allowing the tumor to grow unchecked.

By blocking these signals, researchers can effectively “unmask” the cancer. This approach is being validated in preclinical models for aggressive cancers, including triple-negative breast cancer and ovarian cancer, where traditional chemotherapy often falls short.

The Rise of Bispecific ADCs: A Double-Edged Sword

While monoclonal antibodies are powerful, the industry is moving toward more complex modalities. The Antibody-Drug Conjugate (ADC) is the current “hot” technology, acting as a guided missile that delivers a toxic payload directly to a cancer cell.

The next evolution is the bispecific ADC. Instead of targeting one protein, these molecules target two. A prime example is the development of agents like PHST677, which targets both CDH1 and Nectin-4.

This dual-action approach creates a synergistic effect:

• Immune Engagement: One arm blocks the “don’t eat me” signal (CDH1), triggering macrophages to attack.
• Direct Cytotoxicity: The other arm (Nectin-4) ensures the toxic payload is delivered precisely into the tumor cell.

This “orthogonal” mechanism—combining immune activation with direct killing—is designed to overcome the resistance mechanisms that often render single-target therapies ineffective over time.

Precision Targeting: Reducing “Off-Target” Toxicity

One of the biggest hurdles in ADC development is “on-target, off-tumor” toxicity—where the drug attacks healthy cells that happen to express the target protein. The trend toward co-expression requirements is the solution.

By designing a bispecific ADC that requires both targets (like CDH1 and Nectin-4) to be present on the cell surface before the payload is delivered, the window of safety widens. Since these two proteins are co-expressed in high concentrations in breast, bladder, colorectal, and lung cancers, but rarely together in healthy tissue, the treatment becomes far more selective.

This precision is essential for improving the quality of life for patients, reducing the grueling side effects typically associated with systemic chemotherapy.

Future Outlook: The Integrated Pipeline

Looking ahead, we expect to see a surge in “combination cocktails” that merge innate and adaptive immunity. Imagine a treatment regimen where a macrophage-activator (like an anti-CD24 or anti-CDH1 agent) “primes” the tumor, making it visible and vulnerable, followed by a T-cell activator or a bispecific ADC to deliver the final blow.

The integration of functional genomic screening—using AI and high-throughput data to find these targets—will accelerate this process. We are moving away from “one size fits all” oncology toward a model where a patient’s specific tumor protein expression profile dictates the exact combination of checkpoints to be blocked.

For those tracking clinical progress, keeping an eye on ClinicalTrials.gov for Phase 1 and 2 data on macrophage-directed therapies will be crucial in the coming years.

Frequently Asked Questions

What is a macrophage checkpoint inhibitor?
It is a drug that blocks the “don’t eat me” signals (checkpoints) on the surface of cancer cells, allowing macrophages—the innate immune system’s scavengers—to recognize and destroy the tumor.

How does a bispecific ADC differ from a standard ADC?
A standard ADC targets one protein to deliver a drug. A bispecific ADC targets two different proteins, which can increase the precision of the delivery and allow the drug to perform two functions simultaneously (e.g., immune activation and cell killing).

Which cancers are most likely to benefit from CDH1 targeting?
Cancers that show high upregulation of CDH1 and Nectin-4, including breast, bladder, colorectal, lung, and gastric cancers, are the primary candidates for these emerging therapies.